PCI + TAVR Combination (Oct 2025)
PCI + TAVR Combination (Oct 2025)
ScienceDirect — October 10, 2025.
keynotes:
1. Study (2019–2024, >200 patients) compared simultaneous PCI/TAVR vs. staged PCI then TAVR.
2. In-hospital outcomes: similar mortality (2% vs. 4%), no excess stroke, MI, or AKI.
3. 3-year results: combined PCI/TAVR showed better survival (+68 days) and less bleeding.
4. Authors conclude the simultaneous approach is safe and may offer short- and long-term benefits
5. Antithrombotic Therapy After Combined PCI + TAVR
1. Goal: Balance thrombosis prevention with bleeding risk after simultaneous PCI and TAVR.
2. Recommended Approach:
* DAPT (Aspirin + Clopidogrel) for 1–6 months, then Aspirin alone long-term.
* If oral anticoagulation (OAC) is needed (e.g., for AF), use OAC + Clopidogrel for 1–3 months, then OAC alone.
* Triple therapy (OAC + DAPT) should be avoided or limited to ≤1 month in high ischemic risk.
3. TAVR Only: Single antiplatelet therapy (Aspirin) is usually sufficient unless another indication for OAC exis
